These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 20519399

  • 21. Antibody-Induced Internalization of the Human Respiratory Syncytial Virus Fusion Protein.
    Leemans A, De Schryver M, Van der Gucht W, Heykers A, Pintelon I, Hotard AL, Moore ML, Melero JA, McLellan JS, Graham BS, Broadbent L, Power UF, Caljon G, Cos P, Maes L, Delputte P.
    J Virol; 2017 Jul 15; 91(14):. PubMed ID: 28468888
    [Abstract] [Full Text] [Related]

  • 22. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
    Liang B, Ngwuta JO, Herbert R, Swerczek J, Dorward DW, Amaro-Carambot E, Mackow N, Kabatova B, Lingemann M, Surman S, Yang L, Chen M, Moin SM, Kumar A, McLellan JS, Kwong PD, Graham BS, Schaap-Nutt A, Collins PL, Munir S.
    J Virol; 2016 Nov 01; 90(21):10022-10038. PubMed ID: 27581977
    [Abstract] [Full Text] [Related]

  • 23. GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process.
    Perron M, Stray K, Kinkade A, Theodore D, Lee G, Eisenberg E, Sangi M, Gilbert BE, Jordan R, Piedra PA, Toms GL, Mackman R, Cihlar T.
    Antimicrob Agents Chemother; 2015 Dec 14; 60(3):1264-73. PubMed ID: 26666922
    [Abstract] [Full Text] [Related]

  • 24. Clinical Potential of Prefusion RSV F-specific Antibodies.
    Rossey I, McLellan JS, Saelens X, Schepens B.
    Trends Microbiol; 2018 Mar 14; 26(3):209-219. PubMed ID: 29054341
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of a synthetic peptide as a replacement for the recombinant fusion protein of respiratory syncytial virus in a potency ELISA.
    McGivney JB, Bishop E, Miller K, Casas-Finet J, Yang H, Wei Z, Strouse R, Schenerman M.
    J Pharm Biomed Anal; 2011 Feb 20; 54(3):572-6. PubMed ID: 20943340
    [Abstract] [Full Text] [Related]

  • 26. Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein.
    Magro M, Andreu D, Gómez-Puertas P, Melero JA, Palomo C.
    J Virol; 2010 Aug 20; 84(16):7970-82. PubMed ID: 20534864
    [Abstract] [Full Text] [Related]

  • 27. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection.
    Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V, Millar A, Power UF, Stortelers C, Allosery K, Melero JA, Depla E.
    Antimicrob Agents Chemother; 2016 Jan 20; 60(1):6-13. PubMed ID: 26438495
    [Abstract] [Full Text] [Related]

  • 28. Neutralizing activity of anti-respiratory syncytial virus monoclonal antibody produced in Nicotiana benthamiana.
    Pisuttinusart N, Rattanapisit K, Srisaowakarn C, Thitithanyanont A, Strasser R, Shanmugaraj B, Phoolcharoen W.
    Hum Vaccin Immunother; 2024 Dec 31; 20(1):2327142. PubMed ID: 38508690
    [Abstract] [Full Text] [Related]

  • 29. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.
    Resch B.
    Hum Vaccin Immunother; 2017 Sep 02; 13(9):2138-2149. PubMed ID: 28605249
    [Abstract] [Full Text] [Related]

  • 30. Respiratory Syncytial Virus and Human Metapneumovirus Infections in Three-Dimensional Human Airway Tissues Expose an Interesting Dichotomy in Viral Replication, Spread, and Inhibition by Neutralizing Antibodies.
    Kinder JT, Moncman CL, Barrett C, Jin H, Kallewaard N, Dutch RE.
    J Virol; 2020 Sep 29; 94(20):. PubMed ID: 32759319
    [Abstract] [Full Text] [Related]

  • 31. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
    Patel N, Massare MJ, Tian JH, Guebre-Xabier M, Lu H, Zhou H, Maynard E, Scott D, Ellingsworth L, Glenn G, Smith G.
    Vaccine; 2019 Sep 24; 37(41):6112-6124. PubMed ID: 31416644
    [Abstract] [Full Text] [Related]

  • 32. Immune Prophylaxis Targeting the Respiratory Syncytial Virus (RSV) G Protein.
    Bergeron HC, Murray J, Arora A, Nuñez Castrejon AM, DuBois RM, Anderson LJ, Kauvar LM, Tripp RA.
    Viruses; 2023 Apr 27; 15(5):. PubMed ID: 37243153
    [Abstract] [Full Text] [Related]

  • 33. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease.
    Feltes TF, Sondheimer HM, Tulloh RM, Harris BS, Jensen KM, Losonsky GA, Griffin MP, Motavizumab Cardiac Study Group.
    Pediatr Res; 2011 Aug 27; 70(2):186-91. PubMed ID: 21522037
    [Abstract] [Full Text] [Related]

  • 34. A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways.
    Piedimonte G, King KA, Holmgren NL, Bertrand PJ, Rodriguez MM, Hirsch RL.
    Pediatr Res; 2000 Mar 27; 47(3):351-6. PubMed ID: 10709734
    [Abstract] [Full Text] [Related]

  • 35. Murine Pneumonia Virus Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus from an Added Gene Is Highly Attenuated and Immunogenic in Rhesus Macaques.
    Brock LG, Liu X, Liang B, Lingemann M, Liu X, Herbert R, Hackenberg AD, Buchholz UJ, Collins PL, Munir S.
    J Virol; 2018 Sep 01; 92(17):. PubMed ID: 29925656
    [Abstract] [Full Text] [Related]

  • 36. Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection.
    Tiwari PM, Vanover D, Lindsay KE, Bawage SS, Kirschman JL, Bhosle S, Lifland AW, Zurla C, Santangelo PJ.
    Nat Commun; 2018 Oct 01; 9(1):3999. PubMed ID: 30275522
    [Abstract] [Full Text] [Related]

  • 37. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab.
    Wu H, Pfarr DS, Losonsky GA, Kiener PA.
    Curr Top Microbiol Immunol; 2008 Oct 01; 317():103-23. PubMed ID: 17990791
    [Abstract] [Full Text] [Related]

  • 38. Structural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies.
    Jones HG, Ritschel T, Pascual G, Brakenhoff JPJ, Keogh E, Furmanova-Hollenstein P, Lanckacker E, Wadia JS, Gilman MSA, Williamson RA, Roymans D, van 't Wout AB, Langedijk JP, McLellan JS.
    PLoS Pathog; 2018 Mar 01; 14(3):e1006935. PubMed ID: 29509814
    [Abstract] [Full Text] [Related]

  • 39. Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis.
    Sun M, Lai H, Na F, Li S, Qiu X, Tian J, Zhang Z, Ge L.
    JAMA Netw Open; 2023 Feb 01; 6(2):e230023. PubMed ID: 36800182
    [Abstract] [Full Text] [Related]

  • 40. Analysis of respiratory syncytial virus fusion protein from clinical isolates of Korean children in palivizumab era, 2009-2015.
    Choi SH, Park KS, Kim YJ.
    J Infect Chemother; 2019 Jul 01; 25(7):514-519. PubMed ID: 30885457
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.